Solos Launches Next-Generation Smart Glasses with Seamless Voice Control and Advanced Video Capabilities
With intuitive interaction, superior sound, advanced video capabilities, and camera-enabled AI, Solos' AirGo™ A5 and AirGo™ V2 set a new benchmark for wearable intelligence
HONG KONG, June 26, 2025 /PRNewswire/ -- Solos®, a leading innovator in the world of smart glasses and wearable AI, yesterday announced the launch of its next-generation of smart glasses at the Smart Glasses Symposium 2025 in Hong Kong. Expanding its AirGo product line, Solos introduces the AirGo™ A5, the latest evolution in audio-focused smart eyewear designed for hands-free access to everyday AI, and the AirGo™ V2, the company's most advanced visual AI glasses to date, featuring live video capabilities, an ultra-slim 16MP camera, and more.
The new releases represent a major leap forward in Solos' mission to make wearable AI more intuitive, accessible, and integrated into daily life. The launch also marks the beginning of a new phase for Solos' open ecosystem, with select Software Development Kit (SDK) partners already working to build innovative applications on the platform, unlocking even greater customization and AI-powered use cases across health, lifestyle, and productivity.
"With AirGo™ A5 and V2, we're not just introducing new features, we're changing the way people interact with AI in everyday life," said Kenneth Fan, co-founder of Solos. "These new generations reflect our vision for smart living, where wearable tech works quietly in the background to support your day, not disrupt it."
Solos AirGo™ A5: Smarter, More Seamless Everyday AIIn a world of increasingly complex tech, AirGo™ A5 stands out by doing more with less, bringing rich audio, intuitive AI, and effortless functionality into a familiar, lightweight form. Designed for users who want everyday glasses and intelligent features without the bulk or distraction of traditional wearables, the fifth-generation A5 refines Solos' audio-first experience into something you can wear all day.
The A5 features automatic power-on/off for effortless activation and hands-free wake-up word functionality, letting users simply say "Hey Solos" to engage AI tools like SolosChat without reaching for a phone. Whether queuing up a warm-up routine, finding a dinner recipe, or replying to a message while on the go, A5 integrates real-time assistance into everyday routines.
Natural, fluid interactions are now even more seamless, allowing users to jump in with follow-up questions, just like talking to a friend. Upgraded directional audio minimizes sound leakage for a more private listening experience, while enhanced bass delivers richer, deeper sound quality across music, calls, and voice responses.
Compatible with all frame fronts in the existing AirGo 3 lineup, the AirGo™ A5 offers an easy upgrade path for current users, blending advanced smart features into the style and comfort of everyday eyewear.
Solos AirGo™ V2: Next-Level Vision and AI in the Slimmest Smartglasses YetThe second generation of Solos' Vision AI smartglasses, the AirGo™ V2, pushes wearable technology further with a powerful combination of camera, AI, and real-time connectivity features, all in a slim, feather-light design made for all-day comfort. Equipped with the world's slimmest 16MP camera featuring advanced Electronic Image Stabilization (EIS), users can capture high-resolution images and Full HD video with incredible clarity, even during movement. It's a go-to tool for travelers, content creators, and anyone wanting to document and share life in the moment.
New to this model is live video streaming powered by ultra-low-power Wi-Fi, enabling real-time sharing without sacrificing battery life. The AirGo™ V2 also introduces SolosChat 3.0, a multi-modal AI platform that combines image, video, audio, and text for deeper, more dynamic interactions. Whether it's identifying objects, translating signs, or getting quick answers from multiple AI models, including ChatGPT, Claude, Gemini, and DeepSeek, the experience is built for smart, seamless living.
The AirGo™ V2 retains all the intuitive user features introduced in the A5, including auto power-on/off, wake-up word activation, natural, interruptible conversation, and enhanced directional audio for private listening. It continues Solos' signature modular system equipped with SmartHinge™, allowing users to easily swap out frame fronts to match their style. A swappable battery also provides added flexibility for those looking to extend video recording time and power through longer days. Thoughtfully designed with adjustable nose pads and temple tips, AirGo™ V2 blends style, comfort, and advanced functionality in one unified platform.
Solos is the Leading Smartglasses Platform with Strategic SDK PartnersAs part of its open platform approach for design and software, Solos is working with select SDK partners to explore new AI-driven applications across accessibility, consumer technology, and healthcare. Initial collaborations include Envision, Deutsche Telekom, and The Hong Kong Polytechnic University, which is piloting speech therapy use cases. These partnerships highlight the growing potential for smartglasses to support real-world needs across industries and Solos' open architecture to work with partners for smart glasses development.
Availability and PricingThe Solos AirGo™ A5 will be available starting in Q3 2025, with presales beginning in August, starting at US$249. The AirGo™ V2 is expected to launch in Q4 2025 and will start at US$299. Both models will be available at solosglasses.com.
Additional information and images can be found in the press kit here.
About Solos:Solos is developing the world's most advanced smart glasses technology with a human-first approach. Born out of Kopin Corporation (NASDAQ: KOPN) with MIT engineers, Solos combines industry-leading wearable electronics with the comfort and style of traditional eyewear. With an IP portfolio of over 100 patents and patent applications, the 4x CES Innovation award-winning AirGo technology is changing how we interact with the world. For more information, visit www.solosglasses.com.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/solos-launches-next-generation-smart-glasses-with-seamless-voice-control-and-advanced-video-capabilities-302492215.html
SOURCE Solos Technology Limited
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Joor's Solution to Fashion's Need for Speed is a Digital Trade Show
In today's retail relay, growth hinges on handing buyers the baton of evergreen bestsellers and fresh-drop stock primed to ship at the speed of style. After all, McKinsey reported last November, one-third of consumers now expect same-day delivery to keep pace with their fashion fix. In response to these evolving demands, Joor developed a first-of-its-kind digital show to unite fashion brands with inventory available to sell (ATS) now. The fashion apparel sector's wholesale management ecosystem is calling it the Ready-To-Ship Style digital event, as developed to address the evolving needs of the industry's retail landscape. More from Sourcing Journal FedEx Faces $170M in Tariff Headwinds as US Cracks Down on De Minimis China Port Volumes Hit Record Highs on US Tariff Truce Footwear Firms Rejiggering Supply Chains Will See Long-Term Benefits 'Brands are seeking efficient ways to sell through existing inventory, while retailers require the agility to place orders closer to delivery, minimizing risk by reacting to trends and real-time product performance,' said Amanda McCormick Bacal, senior vice president of marketing at Joor. 'By focusing on available-to-sell inventory, this groundbreaking digital experience provides access to products before prices are impacted by upcoming tariffs, as well as a showcase for evergreen styles which have become increasingly vital to retailers' assortments.' The digital trade show, hosted on Joor Passport, features 145 brands—including Mother Denim, Juicy Couture and Farm Rio—all with ATS inventory. Participating players can showcase brand bestsellers, evergreen pieces and carryover styles to 'maximize visibility of current stock,' Joor said, 'and drive sales ahead of the upcoming tariff changes.' Retailers looking to address these evolving market needs quickly, meanwhile, can now source styles in stock and ready to ship rather than placing orders to be delivered six months later. Joor's exclusive transaction data revealed several 'seismic shifts' within the luxury wholesale fashion industry over the past five years. Retailers are increasingly placing orders on shorter lead times, the data found, and placing smaller initial orders to save more of the company's buying budget for in-season purchases. In fact, per the New York-based platform, the average time from a wholesale order being placed to the product shipping has fallen 66 percent—from a high of 253 days in 2019 to just 86 days in 2024. In addition, evergreen styles continue to signify the climbing importance of such core items' driving overall sales volumes—growing from 37 percent of gross merchandise value (GMV) on Joor in 2019 to 47 percent in 2024. 'The fact that nearly half of total transaction volume is now dedicated to evergreen products demonstrates brands continued focus on maximizing best sellers and retailers' continued desire to invest in proven commercial winners,' Joor said. Looming tariffs seriously influence the wholesale fashion market's need for speed as well. Joor's tariff survey from April confirmed that 85 percent of brands anticipate increasing prices because of global tariffs, creating an urgency for retailers to order and receive goods in advance of these price hikes. The Joor Ready-To-Ship Style passport show runs until August 18.
Bloomberg
13 minutes ago
- Bloomberg
Macau Gaming Revenue Soars Past Estimate on Concert Fervor
Macau's monthly gaming revenue rose 19% in June, exceeding analyst expectations as visitors poured in to the world's biggest gambling hub for Cantonese pop concerts and other entertainment offerings. Gross gaming revenue reached 21.1 billion patacas ($2.6 billion) for the month, according to data released by the Gaming Inspection and Coordination Bureau on Tuesday. That was better than the median analyst estimate of a 9.4% year-on-year increase, and marks a return to 88% of the pre-pandemic level seen in 2019.
Yahoo
18 minutes ago
- Yahoo
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan
-- Enabling Scalable, Non-Viral Cell Engineering for Research, Biomanufacturing, and Therapeutic Development -- TOKYO, July 01, 2025--(BUSINESS WIRE)--The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHCbi"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo, hereafter referred to as "PHCHD") announces it has signed an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte ExPERT platform(*1) in Japan. In Singapore, SciMed (Asia) Pte Ltd, a subsidiary of PHCHD, separately entered into an exclusive distribution agreement with MaxCyte and launched the ExPERT platform in the country in June. MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics. Under this partnership, PHCbi will offer sales and service support for MaxCyte's instruments, consumables, and solutions, providing researchers and manufacturers with access to a clinically proven, non-viral cell engineering platform. MaxCyte's ExPERT instrument portfolio is the next generation of leading, clinically and commercially validated electroporation technology for complex and scalable cell engineering. By enabling high transfection efficiency and cell viability, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. PHCbi will distribute and support the full range of MaxCyte platforms covered under this agreement, including the ExPERT ATx®, ExPERT STx®, ExPERT GTx® and ExPERT VLx® as well as related consumables such as processing assemblies and electroporation buffers. These platforms are used by researchers worldwide and have been referenced in more than 70 clinical programs as of Q1 2025. Chikara Takauo, Director of PHC Corporation and General Manager of PHCbi, commented: "We are pleased to add the MaxCyte's ExPERT instruments to our cell culture technology portfolio. Guided by our vision of 'contributing to the evolution and progress of therapeutic modalities,' we are committed to expanding new solutions that address the challenges of QCD (Quality, Cost, and Delivery) in cell and gene therapy (CGT) manufacturing processes. The addition of MaxCyte's ExPERT portoflio allows us to better support scientists and cell therapy developers by providing them with a powerful, non-viral tool to advance their cell-based research and development processes and ultimately accelerate the adoption of CGT." The addition of MaxCyte's ExPERT platform complements PHCbi's ongoing efforts to further enhance the efficiency of CGT development and manufacturing processes while improving cell quality and safety. PHCbi recently introduced the LiCellMoTM live-cell metabolic analyzer(*2) for research use, incorporating PHC's core In-Line Monitoring technology. In addition, PHCbi is developing the LiCellGrowTM cell expansion system, which is being designed to optimize the cell culture environment by automatically exchanging culture medium based on the metabolic state of cells. Together with the MaxCyte's platform, these solutions reflect PHCbi's commitment to delivering comprehensive support for researchers and developers working in areas such as regenerative medicine, immunotherapy, and bioproduction as well as accelerating cell-based innovation in Japan and Singapore. PHCbi will showcase the ExPERT Platform at the 7th Regenerative Medicine EXPO Tokyo 2025 in Japan, which will be held at Japan's Tokyo Big Sight from July 9 to July 11, 2025. 7th Regenerative Medicine EXPO Tokyo 2025Dates: July 9 (Wed.) - 11 (Fri.), 2025Venue: Tokyo Big Sight Japan, West Exhibition Halls (PHCbi Booth No.: W5-30)Official Website: INTERPHEX Week Tokyo / Regenerative Medicine Expo Tokyo (*1) Product information: MaxCyte's instruments are not classified as a medical device. (*2) Product information: Live Cell Metabolic Analyzer | PHCbi About the Biomedical Division of PHC CorporationEstablished in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TSE 6523), a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The Biomedical Division supports the life sciences industry helping researchers and healthcare providers in around 110 countries and regions through its PHCbi-branded laboratory and equipment and services including CO2 incubators and ultra-low temperature About PHC Holdings Corporation (PHC Group)PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. PHC Group's consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 About SciMed (Asia) Pte LtdSciMed (Asia) Pte Ltd, headquartered in Singapore, is an established and leading provider of products and services for biomedical, life sciences, healthcare, drug discovery, pharmaceutical, laboratories, industrial tests, and agricultural markets. SciMed has become the wholly owned subsidiary of PHC Holdings Corporation in 2023, advancing sales and marketing in life sciences business across Southeast Asia, India, and About MaxCyte, MaxCyte, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation™ technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. View source version on Contacts Contact for media inquiries:Investor Relations & Corporate Communications DepartmentPHC Holdings CorporationTEL: +81-3-6778-5311E-mail: phc-pr@ Contact for product and service:Marketing Department, Biomedical Division PHC CorporationE-mail: Sign in to access your portfolio
